FDA Restricts Access to Avandia

Citing heart risks, agency also orders review of key research on cardiovascular impact; European regulators suspend drug's sales

HealthDay SHARE

Since there is a similar alternative, Actos, that hasn't been shown to increase cardiovascular risk, "you would think there would be very little place for Avandia," he said.

Goldberg said he will no longer prescribe Avandia, except to patients who have been using it for many years. In addition, going through the process to qualify patients for Avandia will deter many doctors from even considering Avandia as a treatment for diabetes, he said.

More information

For more information on diabetes, visit the U.S. National Library of Medicine.

Copyright © 2011 HealthDay. All rights reserved.